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Abstract: 
The oral route of drug administration is the most common and preferred method of delivery due to convenience 
and ease of ingestion but it is problematic if the drug is poorly soluble or poor membrane penetrability. 
Although salt formation, solublization, particle size reduction have commonly used to increase dissolution rate 
and thereby oral absorption and bioavailability of low water soluble drugs there is practical limitation to these 
techniques. Among numerous ways of enhancing drug dissolution solid dispersion of drug in a water soluble 
polymer is one of the promising technique. Solid dispersion (SD) is defined as the dispersion of one or more 
active ingredients in inert carriers at solid state prepared by fusion, solvent or solvent fusion methods.The study 
was aimed to formulate solid dispersion tablet of Terbinafine Hydrochloride by using carriers polyethylene 
glycol 6000 (by melting method) and maltodextrin,urea  in the drug carrier ratio of 1:1, 1:2 and 1:3. The 
prepared solid dispersions were characterized for their drug content, thermal studies, infrared spectral studies, 
aqueous solubility studiesand %yield.. From the results, it was clear that solid dispersion formulation showed 
improved dissolution rate compared to  pure drug and physical mixture.  
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INTRODUCTION: 
In order to ensure the optimum therapeutic effect of 
drug it is necessary to prepare the proper dosage 
form. To formulate an effective dosage form the 
drug must possess some important characteristics 
and one of them is the solubility in water. Since 
only dissolved drug can pass the gastrointestinal 
membrane, dissolution is one that affect the 
systemic absorption. Among all the routes of drug 
administration, oral drug delivery is the simplest 
and easiest way of administering drugs, because of 
the greater stability, smaller bulk, possess accurate 
dose and easy to manufacture. The oral route of 
drug administration is the most common and pre-
ferred method of drug delivery due to convenience 
and ease of inges-tion. Poorly water soluble drugs 
having slow drug absorption leads to inadequate 
and variable bioavailability and gastrointestinal 
mu-cosal toxicity. This poor oral bioavailability of 
the drug is the major challenging task for  
designing the oral dosage forms. The poor oral 
bioavailability of the drug is due to  low solubility, 
low dissolution of the drug rather than permeation 
of the drug through epithelia of gas-trointestinal 
tract[1] . Drug absorption from the gastrointestinal 
tract can be limited by a number of factors; most 
significant contributors are poor aqueous solubility 
& poor membrane permeability of the drug 
molecule. When delivering an active agent orally, it 
must first dissolve in gastric and/or intestinal fluids 
before it  can  permeate the membranes of the GI 
tract to reach systemic circulation. Hence two areas 
of pharmaceutical research that focus on improving 
the oral bioavailability of active agents include 
enhancing solubility and dissolution rate of poorly 
water soluble drugs & enhancing permeability of 
poorly water-soluble drugs. 
Therefore, most of the new chemical entities under 
development these days are intended to be used as 
a solid dosage form which produces an effective 
reproducible in vivo plasma concentration after oral 
administration. In fact, most new chemical entities 
are poorly soluble drugs, not well-absorbed after 
oral administration, which can distract from the 
drug’s inherent efficacy.  
There are various techniques available to improve 
the solubility of poorly soluble drugs, such as 
micronization, nanosuspension, modification of the 
crystal habits, eutectic mixtures, solid dispersions, 
micro emulsions, self micro emulsifying drug 
delivery systems, cyclodextrin inclusion and lipid 
based delivery systems etc[2]The most promising 
method for promoting dissolution is the formation 
of solid dispersion in a proper carrier. The 
conventional methods for reducing particle size 
include trituration, ball milling, grinding, etc. 
Sekiguchi and Obi first introduced the concept of 
using solid dispersion to improve bioavailability of 
poorly water soluble drugs in 1961.  
Definition of solid dispersion:- 
The term solid dispersion refers to the dispersion of 
one or more active ingredients in an inert carriers 
or matrix at solid state prepared by melting , 
solvent evaporation or other technique of solid 
dispersion. Solid dispersions (SDs) have 
traditionally been used as an effective method to 
improve the dissolution proper-ties and 
bioavailability of poorly water-soluble drugs. In 
solid dispersions systems, a drug may exist as an 
amorphous form in polymeric carriers, and this 
may result in improved solubility’s and dissolution 
rates as compared with crystalline material. Drugs 
molecularly dispersed in polymeric carriers may 
achieve the highest levels of particle size reduction 
and surface area enhancement, which result in im-
proved dissolution rates [3] 
Solid dispersions are prepared to:  
     1. To improve drug solubility.  
    2. To improve drug stability.  
    3. To mask the bitter taste of drug.  
    4. To obtain required release profile 
Mechanism 
The basic mechanisms responsible for increasing 
solubility of drugs are:- 
Wetting 
Reduced particle size or particle agglomeration 
Soluble complex formation   
 
Advantages of Solid Dispersions:- 
 Particles with reduced particle size.  
 Particles with improved wettability.  
 Particles with higher porosity of drug.  
 Drug in amorphous form.  
 To improve porosity of drug.  
 To decrease the crystalline structure of 
drug in to amorphous form.  
 To improve dissolvability in water of a 
poorly water-soluble drug in a 
pharmaceutical. [4] 
 
Disadvantages of Solid Dispersions:- 
 The major disadvantages of SDs are 
related to their instability.  
 Several systems have shown changes in 
crystallinity and a decrease in dissolution 
rate on aging.  
 By absorbing moisture, phase separation, 
crystal growth or a change from 
metastable crystalline form to stable form 
can take place which leads to the reduction 
of drug solubility. 
 Moisture and temperature have more of 
deteriorating effect on solid dispersions 
than on physical mixtures. Sometimes it is 
difficult to handle because of tackiness [7] 
 Several systems have shown changes in 
crystallanity and a decrease in dissolution 
rate on aging.  
 Moisture and temperature have more of 
deteriorating effect on solid dispersions. 
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During formulation sometimes it may form hard 
lump which  is very difficult to break on large 
scale. 
Techniques of solid dispersion:- 
1) Melting (Fusion) Method 
2) Solvent Evaporation 
3) Kneading Method 
4) Spray Drying 
5) Hot Melt Extrusion  
1. Melting method:- The melting or fusion 
method, first proposed by (Sekiguchi and Obi 
1961) involves the preparation of physical mixture 
of a drug and a water-soluble carrier and heating it 
directly until it melted. The melted mixture is then 
solidified rapidly in an ice-bath under vigorous 
stirring.  The final solid mass is crushed, pulverized 
and sieved. [8] 
Ex.- Albendazole and urea solid dispersion  
2. Solvent method:- In this method, the physical 
mixture of the drug and carrier is dissolved in a 
common solvent, which is evaporated until a clear, 
solvent free film is left.  [5]The film is further dried 
to constant weight.  
Advantage:- The main advantage of the solvent 
method is thermal decomposition of drugs or 
carriers can be prevented because of the relatively 
low temperatures required for the evaporation of 
organic solvents.[9] 
Ex.- solid dispersion sulfa thiazine and urea  
3. Melting solvent method (Melt Evaporation):- 
It involves preparation of solid dispersions by 
dissolving the drug in a suitable liquid solvent and 
then incorporating the solution directly into the 
melt of polyethylene glycol, which is then 
evaporated until a clear, solvent free film is left. 
The film is further dried to constant weight[6]. The 
5–10% (w/w) of liquid compounds can be 
incorporated into polyethylene glycol 6000 without 
significant loss of its solid property.  
4. Melt extrusion method:- The drug/carrier mix 
is typically processed with a twin-screw extruder. 
The drug/carrier mix is simultaneously melted, 
homogenized and then extruded and shaped as 
tablets, granules, pellets, sheets, sticks or powder. 
[5]An important advantage of the hot melt 
extrusion method is that the drug/carrier mix is 
only subjected to an elevated temperature for about 
1 min, which enables drugs that are somewhat 
thermo labile to be processed.[10] 
Tolterodine is an antimuscarinic drug that is used to 
treat urinary inconvience. Tolterodine acts on M2 
and M3 subtypes of muscarinic 
receptors.Tolterodine are a competitive muscarinic 
receptor antagonist. Both urinary bladder 
contraction and salivation are mediated via 
cholinergic muscarinic receptors. After oral 
administration, tolterodine is metabolized in the 
liver, resulting in the formation of the 5-
hydroxymethyl derivative, a major 
pharmacologically active metabolite.[8] The 5-
hydroxymethyl metabolite, which exhibits an 
antimuscarinic activity similar to that of 
tolterodine, contributes significantly to the 
therapeutic effect. Both tolterodine and the 5-
hydroxymethyl metabolite exhibit a high specificity 
for muscarinic receptors, since both show 
negligible activity or affinity for other 
neurotransmitter receptors and other potential 
cellular targets, such as calcium channels. 
[11]Tolterodine has a pronounced effect on bladder 
function. The main effects of tolterodine are an 
increase in residual urine, reflecting an incomplete 
emptying of the bladder, and a decrease in detrusor 
pressure, consistent with an antimuscarinic action 
on the lower urinary tract. Both tolterodine and its 
active metabolite, 5-hydroxymethyltolterodine, act 
as competitive antagonists at muscarinic receptors. 
This antagonism results in inhibition of bladder 
contraction, decrease in detrusor pressure, and an 
incomplete emptying of the bladder.[12] 
The drug is poorly soluble in water inorder to 
increase the solubility and to enhance the oral 
bioavailability it is formulated in the form of solid 
dispersion using urea,PEG6000,pvp,urea and 
maltodextrin  using different methods. 
 
MATERIALS AND METHODS: 
Materials:- Tolteridone tartarate was   obtained as 
gift sample from hetero , India. Maltodextrin was 
procured from Himedia laboratories 
pvt.Ltd,Dindori,India . Polyvinyl pyrrolidone was 
procured from lobachemie laboratory and 
chemicals, Pvt. Ltd, Mumbai, India .urea was 
procured from universal laboratories Pvt, Ltd, 
Raheja centre, Mumbai, India , polyethylene glycol 
6000was procured from lobachemie reagents and 
fine chemicals,Mumbai,India. All chemicals and 
solvents used were of analytical grade. 
 Methods 
Preparation of solid dispersion by melting 
method 
In melting method the drug and carrier 
polyethylene glycol 6000 were mixed in 1:1, 1:2, 
and 1:3 ratios in a china dish and heated on a 
paraffin bath. The mixture was poured on a tile and 
cooled. The resulted solidified mass was dried 
pulverised and passed through sieve # 100. 
Preparation of solid dispersion by solvent 
evaporation method 
In solvent evaporation method, the drug and carrier 
polyvinyl pyrrolidone   were mixed in 1:1, 1:2 and 
1:3 ratios in chloroform. Solvent was removed by 
evaporation under reduced pressure. The mass was 
pulverised and passed through sieve # 100. 
Preparation of solid dispersion by fusion method 
Accurately weighed quantity of tolteridone tartarate 
and  urea were mixed in a ratio 1:1,1:2,1:3 were   
taken in a china dish[14] . The ingredients were 
melted in a china dish and the contents   of the 
china dish were allowed to cool on a ice bath .The 
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dispersion obtained was passed through the sieve 
and crushed in a  mortar .The obtained solid 
disperison was packed properly. 
Preparation of solid dispersion by fusion method 
Accurately weighed quantity of tolteridone tartarate 
and  maltodextrin  were mixed in a ratio 1:1,1:2,1:3  
and were   taken in a china dish . The ingredients 
were melted in a china dish and the contents   of the 
china dish were allowed to cool on a ice bath .The 
dispersion obtained was passed through the sieve 
and crushed in a  mortar .the obtained solid 
disperison was packed properly.[13] 
Pre -formulation studies:- 
1. Melting point determination:-The melting 
point of the sample was determined by the 
capillary tube method. 
2. Ft-ir study:- Infra red studies was carried out 
to rule out   the interaction between drug and 
carrier used in formulation of solid dispersion 
by potassium bromide disc method using Infra 
red spectrophotometer. [15] 
Evaluation of Solid Dispersion:- 
1. Thermal studies:-It was carried out to 
ascertain the effect of heating on stability of 
the drug. It is based on thaw point melt method 
by heating drug in capillary melting point tube 
and allowing it to solidify. The melting point 
of rapidly solidifying mass was noted. 
2. Aqueous solubility studies:- It was carried 
out to determine solubility of tolteridone 
tartarate  alone in aqueous medium and also in 
presence of carriers like polyethylene glycol 
6000 and polyvinyl pyrrolidone , urea, 
maltodextrin. This was done by dissolving 
excess drug in different flasks in different 
carriers.[14] 
3. Drug content :-An amount equivalent to 2.0 
mg of (TOL) of finely ground tablets  was 
accurately weighed and transferred into 100 ml 
volumetric flask, the mixture was stirred for 30 
minutes , then   it was kept aside  for five 
minutes and filtered using 0.5 μm filter paper, 
finally a certain portion of the filtrate was 
taken and then  transferred into a series of 10 
ml volumetric flasks .1.0 ml of KMnO4, and 2 
ml Sulfuric acid solutions were pipetted, out  
then different volumes of (TOL) standard 
solution was added, the mixture was  allowed 
to stand for 20 minutes then 2 ml of Methylene 
blue dye was added and finally water was 
added to  make up the volume to 10.0 ml, then 
the absorbance of the solution   was measured 
at 600 nm.[17] 
4. Percentage yield: -Thoroughly dried solid 
dispersions were collected and weighed 
accurately. The percentage yield was then 
calculated using formulae given below 
 
5. Dissolution Studies: The invitro dissolution 
studies were done to compare the rate of 
dissolution of solid dispersions with that of 
pure drug Tolteridone tartarate   and physical 
mixtures. The test was performed in USP 
paddle apparatus using 900ml  acetate buffer 
solution at pH 4.0 and temperature 37+ 10C at  
a stirrer depth of 50 rpm and the 5ml of the 
sample was withdrawn from the dissolution 
flask for a period of series of time intervals 
5,10,15,30,45,60 mins respectively inorder to 
maintain the sink condition. The withdrawn 
samples were estimated in uv-visible 
spectrophotometer at 600nm. 
 
RESULTS AND DISCUSSION: 
1. Ft-ir study:- Infra red spectral analysis 
showed that there was  no interaction  between 
pure drug and solid dispersion.  
2. Thermal study:-Thermal study was carried 
out to ascertain the decomposition of drug. 
This indicated that there was no significant 
change in the melting point of tolteridone 
tartarate  after thermal studies.The results are 
tabulated in table no: 3. 
3. Percentageyield:-Percentage yield of 
different formulationwas determined by 
weighing thesolid dispersion after drying.  The 
percentage yield of different formulation was 
in range of 43.5 - 82.2% 
4. .Drug content analysis:-Drug content of the 
solid dispersions was found to be  in the range 
of 92 % and 98%. All the physical mixtures 
and solid dispersions showed the presence of 
high drug content , it indicates that the drug is 
uniformly dispersed in the powder 
formulation. Therefore, the method used in this 
study appears to be reproducible for 
preparation of solid dispersion. 
5. Solubility studies:-Aqueous solubility studies 
indicated that solubility of tolteridone tartarate 
increased in presence of carriers when 
compared to solubility of drug in distilled 
water. The fast and rapid dissolution of drug 
observed in solid dispersions due to the 
presence of drug in amorphous form. The 
amorphous form has  the highest energy  
compared to pure compound and produces 
faster dissolution. The other factors like 
absence of aggregation, good wettability and 
dispersability might have also contributed to 
the increase in dissolution rate. The results of 
aqueous solubility studies are given in table 
no:4 
 
6. .Dissolution studies:- In vitro dissolution 
studies indicated that as concentration of 
carrier increases, dissolution of drug improved.  
The formulation code F3 (Tolteridone tartarate 
: PEG 6000 = 1:3) showed 97 % release in 
120minutes than other PEG solid dispersions 
whereas the physical mixtures of same 
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formulation released  95.54%in 120 minutes, 
pure drug  released only 28%in 120 
minutes.Compared with the pure drug and 
physical mixture, the dissolution was found to 
increase in the following order. 
Pure drug < Physical mixture < solid 
dispersion 
This may be due to the presence of polymer, 
which increases wetting, and dissolution of the 
drug. Even though the polymer is present in 
the physical mixture the dissolution rate was 
lesser than solid dispersion. This increase in 
dissolution rate of solid dispersion was 
attributed to molecular/ colloidal dispersion of 
drug in mixture. Higher the proportion of 
carrier there was a steep increase in dissolution 
rate of drug . 
 
Table 1: Composition of tolteridone tartarate solid dispersions. 
 
Formulation Code Ingredients Ratio of Solid 
Dispersion 
Type of Disperrsion 
F1 Urea +Drug 1:1 
1:2 
1:3 
solid dispersion 
F2 Polyethylene glycol6000+Drug 1:1 
1:2 
1:3 
solid dispersion 
F3 Maltodextrin+Drug 1:1 
1:2 
1:3 
solid dispersion 
F4 Urea 1:1 
1:2 
1:3 
physical mixture 
F5 Polyethylene glycol6000 1:1 
1:2 
1:3 
physical mixture 
F6 Maltodextrin 1:1 
1:2 
1:3 
physical mixture 
 
Table 2: Thermal study of tolteridone tartarate solid dispersion. 
 
S.NO Melting point  before thermal study Melting point after thermal study 
1 210 205 
2 205 200 
3 210 197 
 
Table 3: Solubility studies of tolteridone tartarate solid dispersion. 
 
Name of the carrier Solubility of tolteridone in different polymers 
 0.25% 0.75% 1% 2% 
PEG6000 10mg/ml 10mg/ml 10mg/ml 18mg/ml 
Maltodextrin 8mg/ml 8mg/ml 7mg/ml 4mg/ml 
urea 11mg/ml 12mg/ml 9mg/ml 7mg/ml 
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Table 4:- Percentage yield of tolteridone tartarate solid dispersion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6:-Dissolution profile of tolteridone tartarate solid dispersion. 
S.
No. 
Batches  Cumulative % Release at Different Time Intervals in min   
  5 10 15 30 45 60 90 120 
1 Tolteridone 
tartarate 
1.343 3.122 4.871 6.442 14.11 16.87 19.79 28.92 
2 F1 17.45 22.83 36.51 42.76 55.56 69.92 74.77 89.61 
3 F2 18.12 23.55 37.11 45.23 67.44 72.12 86.88 97.73 
4 F3 18.23 24.21 39.10 47.98 50.55 63.64 70.11 87.16 
5 F4 15.56 20.11 33.01 40.44 50.75 65.11 73.88 91.90 
6 F5 15.66 28.93 33.67 56.44 60.51 75.64 89.49 95.54 
7 F6 17.23 29.12 34.67 47.55 53.88 69.09 74.66 80.56 
S.NO. Formulation No. % yield 
1 F1 52.1 
2 F2 60.9 
3 F3 67.6 
4 F4 56.0 
5 F5 62.9 
6 F6 61.6 
Table 5:- %Drug content of tolteridone tartarate solid dispersion. 
Formulation Batch Drug Content 
F1 95.87% 
F2 92.23% 
F3 98.33% 
F4 96.73% 
F5 98.67% 
F6 91.12% 
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Fig 1:- Infrared spectrum of pure drug 
 
 
Fig 2: Infrared spectrum of drug and polymers 
 
Fig 3: Infrared spectrum of all the polymers 
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Fig 4:-dissolution profile of solid dispersions. 
 
 
Fig 5: Solid dispersion of tolteridone tartarate using differentpolymers. 
 
CONCLUSION: 
Concept of solid dispersion is very easy approach 
for solubility enhancement when compared with 
other approaches. So we conclude that solubility of 
poorly water soluble drugs, stability of unstable 
drugs and thereby bioavailability can be 
successfully enhanced by solid dispersion 
technique based on reported literature. The increase 
in bioavailability of drug is because of higher 
solubility enhancement. The higher solubility of 
solid dispersions is because of conversion of 
crystalline drug to amorphous form.Among all the 
solid dispersions prepared the dispersion with 
PEG6000 was found to be the best formulation.and 
it was found to be the best carrier for the 
preparation of solid dispersion. 
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